{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:33:01Z","timestamp":1779161581783,"version":"3.51.4"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1P01CA120964"],"award-info":[{"award-number":["1P01CA120964"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Inactivating mutations in either\n                    <jats:italic>TSC1<\/jats:italic>\n                    or\n                    <jats:italic>TSC2<\/jats:italic>\n                    cause Tuberous Sclerosis Complex, an autosomal dominant disorder, characterized by multi-system tumor and hamartoma development. Mutation and loss of function of\n                    <jats:italic>TSC1<\/jats:italic>\n                    and\/or\n                    <jats:italic>TSC2<\/jats:italic>\n                    also occur in a variety of sporadic cancers, and rapamycin and related drugs show highly variable treatment benefit in patients with such cancers. The TSC1 and TSC2 proteins function in a complex that inhibits mTORC1, a key regulator of cell growth, which acts to enhance anabolic biosynthetic pathways. In this study, we identified and validated five cancer cell lines with\n                    <jats:italic>TSC1<\/jats:italic>\n                    or\n                    <jats:italic>TSC2<\/jats:italic>\n                    mutations and performed a kinase inhibitor drug screen with 197 compounds. The five cell lines were sensitive to several mTOR inhibitors, and cell cycle kinase and HSP90 kinase inhibitors. The IC50 for Torin1 and INK128, both mTOR kinase inhibitors, was significantly increased in three TSC2 null cell lines in which TSC2 expression was restored. Rapamycin was significantly more effective than either INK128 or ganetespib (an HSP90 inhibitor) in reducing the growth of TSC2 null SNU-398 cells in a xenograft model. Combination ganetespib-rapamycin showed no significant enhancement of growth suppression over rapamycin. Hence, although HSP90 inhibitors show strong inhibition of TSC1\/TSC2 null cell line growth in vitro, ganetespib showed little benefit at standard dosage in vivo. In contrast, rapamycin which showed very modest growth inhibition in vitro was the best agent for in vivo treatment, but did not cause tumor regression, only growth delay.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0248380","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T13:41:45Z","timestamp":1619185305000},"page":"e0248380","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1\/TSC2 deficient cancer"],"prefix":"10.1371","volume":"16","author":[{"given":"Evelyn M.","family":"Mrozek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineeta","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela A.","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-5219","authenticated-orcid":true,"given":"David J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"pone.0248380.ref001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-genom-083118-015354","article-title":"Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex","volume":"20","author":"CL Salussolia","year":"2019","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"pone.0248380.ref002","doi-asserted-by":"crossref","DOI":"10.1002\/9783527630073","volume-title":"Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics","author":"DJ Kwiatkowski","year":"2010"},{"issue":"2","key":"pone.0248380.ref003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1134\/S0006297914020023","article-title":"Kinase mTOR: regulation and role in maintenance of cellular homeostasis, tumor development, and aging","volume":"79","author":"AA Parkhitko","year":"2014","journal-title":"Biochemistry (Mosc)"},{"key":"pone.0248380.ref004","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"EP Henske","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"pone.0248380.ref005","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"174","author":"AG Robertson","year":"2018","journal-title":"Cell"},{"issue":"7","key":"pone.0248380.ref006","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/ijc.27800","article-title":"Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates","volume":"132","author":"MA Dickson","year":"2013","journal-title":"Int J Cancer"},{"issue":"3","key":"pone.0248380.ref007","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s42255-019-0038-7","article-title":"Molecular logic of mTORC1 signalling as a metabolic rheostat","volume":"1","author":"AJ Valvezan","year":"2019","journal-title":"Nat Metab"},{"issue":"2","key":"pone.0248380.ref008","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cmet.2017.07.001","article-title":"The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway","volume":"26","author":"RL Wolfson","year":"2017","journal-title":"Cell Metab"},{"issue":"4","key":"pone.0248380.ref009","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","article-title":"TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1","volume":"47","author":"CC Dibble","year":"2012","journal-title":"Mol Cell"},{"issue":"5","key":"pone.0248380.ref010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4161\/cbt.2.5.446","article-title":"Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis","volume":"2","author":"DJ Kwiatkowski","year":"2003","journal-title":"Cancer Biol Ther"},{"issue":"6144","key":"pone.0248380.ref011","doi-asserted-by":"crossref","first-page":"1236566","DOI":"10.1126\/science.1236566","article-title":"mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin","volume":"341","author":"SA Kang","year":"2013","journal-title":"Science"},{"issue":"6035","key":"pone.0248380.ref012","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","volume":"332","author":"Y Yu","year":"2011","journal-title":"Science"},{"issue":"5982","key":"pone.0248380.ref013","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1126\/science.1187532","article-title":"mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs","volume":"328","author":"RJ Dowling","year":"2010","journal-title":"Science"},{"issue":"3","key":"pone.0248380.ref014","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","article-title":"Dissecting the role of mTOR: lessons from mTOR inhibitors","volume":"1804","author":"RJ Dowling","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"6035","key":"pone.0248380.ref015","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","volume":"332","author":"PP Hsu","year":"2011","journal-title":"Science"},{"issue":"12","key":"pone.0248380.ref016","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121584","article-title":"Targeting mTOR and Metabolism in Cancer: Lessons and Innovations","volume":"8","author":"C Magaway","year":"2019","journal-title":"Cells"},{"issue":"9","key":"pone.0248380.ref017","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S1470-2045(13)70169-4","article-title":"Inhibition of HSP90 molecular chaperones: moving into the clinic","volume":"14","author":"R Garcia-Carbonero","year":"2013","journal-title":"Lancet Oncol"},{"key":"pone.0248380.ref018","article-title":"The Role of Heat Shock Protein-90 in the Pathogenesis of Birt-Hogg-Dube and Tuberous Sclerosis Complex Syndromes","author":"MR Woodford","year":"2020","journal-title":"Urol Oncol"},{"issue":"8","key":"pone.0248380.ref019","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"J Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"pone.0248380.ref020","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.3892\/mmr.2015.3725","article-title":"Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy","volume":"12","author":"W Cheng","year":"2015","journal-title":"Mol Med Rep"},{"key":"pone.0248380.ref021","first-page":"1849","article-title":"Ganetespib: research and clinical development","volume":"8","author":"K Jhaveri","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"1","key":"pone.0248380.ref022","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"L Neckers","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"pone.0248380.ref023","first-page":"4010","article-title":"Disruption of the EF-2 kinase\/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin","volume":"61","author":"J Yang","year":"2001","journal-title":"Cancer Res"},{"key":"pone.0248380.ref024","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-13-152","article-title":"A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies","volume":"13","author":"JW Goldman","year":"2013","journal-title":"BMC Cancer"},{"issue":"15","key":"pone.0248380.ref025","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/nar\/gks596","article-title":"Primer3\u2014new capabilities and interfaces","volume":"40","author":"A Untergasser","year":"2012","journal-title":"Nucleic acids research"},{"issue":"7391","key":"pone.0248380.ref026","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"J Barretina","year":"2012","journal-title":"Nature"},{"key":"pone.0248380.ref027","unstructured":"The Broad Institute of MIT & Harvard. Tuberous sclerosis 1 2012 [https:\/\/portals.broadinstitute.org\/ccle\/page?gene=TSC1."},{"key":"pone.0248380.ref028","unstructured":"The Broad Institute of MIT & Harvard. Tuberous sclerosis 2 2012 [https:\/\/portals.broadinstitute.org\/ccle\/page?gene=TSC2."},{"issue":"26","key":"pone.0248380.ref029","doi-asserted-by":"crossref","first-page":"16621","DOI":"10.1074\/jbc.273.26.16621","article-title":"Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies","volume":"273","author":"QP Weng","year":"1998","journal-title":"J Biol Chem"},{"issue":"5","key":"pone.0248380.ref030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1541-7786.MCR-12-0605","article-title":"Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis","volume":"11","author":"Y Guo","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"3","key":"pone.0248380.ref031","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.18632\/oncotarget.13989","article-title":"Endometrial cancer cells exhibit high expression of p110beta and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation","volume":"8","author":"T Karlsson","year":"2017","journal-title":"Oncotarget"},{"key":"pone.0248380.ref032","article-title":"Abstract B092: Molecular aberrations of the PI3K-AKT-mTORC1\/C2 pathway in ovarian cancers: a strategy for targeted therapy","volume":"17","author":"P De","year":"2018","journal-title":"Molecular Cancer Therapeutics"},{"issue":"13","key":"pone.0248380.ref033","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.1074\/jbc.C500451200","article-title":"TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase","volume":"281","author":"H Chong-Kopera","year":"2006","journal-title":"J Biol Chem"},{"issue":"8","key":"pone.0248380.ref034","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI200317222","article-title":"Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR","volume":"112","author":"H Zhang","year":"2003","journal-title":"J Clin Invest"},{"issue":"3","key":"pone.0248380.ref035","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1172\/JCI28984","article-title":"PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR","volume":"117","author":"H Zhang","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"pone.0248380.ref036","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.chembiol.2019.02.018","article-title":"Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries","volume":"26","author":"N Moret","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"1","key":"pone.0248380.ref037","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s13277-015-3922-0","article-title":"The anti-ovarian cancer activity by WYE-132, a mTORC1\/2 dual inhibitor","volume":"37","author":"D Zhang","year":"2016","journal-title":"Tumour Biol"},{"issue":"56","key":"pone.0248380.ref038","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","article-title":"The rapamycin-sensitive signal transduction pathway as a target for cancer therapy","volume":"19","author":"M Hidalgo","year":"2000","journal-title":"Oncogene"},{"issue":"24","key":"pone.0248380.ref039","doi-asserted-by":"crossref","first-page":"14253","DOI":"10.1073\/pnas.2332307100","article-title":"Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family","volume":"100","author":"S Fong","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0248380.ref040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.12717\/DR.2014.18.1.065","article-title":"Polo-like kinases (plks), a key regulator of cell cycle and new potential target for cancer therapy","volume":"18","author":"SY Lee","year":"2014","journal-title":"Dev Reprod"},{"issue":"4","key":"pone.0248380.ref041","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.18632\/oncotarget.14268","article-title":"The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models","volume":"8","author":"KW Pajtler","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"pone.0248380.ref042","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/15548627.2016.1263781","article-title":"PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy","volume":"13","author":"S Ruf","year":"2017","journal-title":"Autophagy"},{"issue":"17","key":"pone.0248380.ref043","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-06-0214","article-title":"A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors","volume":"12","author":"LL Garland","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pone.0248380.ref044","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4161\/cc.8.7.8044","article-title":"Targeting mTOR with rapamycin: one dose does not fit all","volume":"8","author":"DA Foster","year":"2009","journal-title":"Cell Cycle"},{"issue":"18","key":"pone.0248380.ref045","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1016\/j.yexcr.2007.06.022","article-title":"Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context","volume":"313","author":"MA Theodoraki","year":"2007","journal-title":"Exp Cell Res"},{"issue":"2","key":"pone.0248380.ref046","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","article-title":"Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy","volume":"11","author":"W Ying","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"pone.0248380.ref047","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molcel.2016.12.020","article-title":"Forging Ahead through Darkness: PCNA, Still the Principal Conductor at the Replication Fork","volume":"65","author":"KN Choe","year":"2017","journal-title":"Mol Cell"},{"key":"pone.0248380.ref048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-61779-860-3_5","article-title":"Detection of apoptosis by TUNEL assay","volume":"887","author":"K Kyrylkova","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"1","key":"pone.0248380.ref049","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/bcr1639","article-title":"Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients","volume":"9","author":"LK Dunnwald","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"7391","key":"pone.0248380.ref050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"MJ Garnett","year":"2012","journal-title":"Nature"},{"key":"pone.0248380.ref051","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","article-title":"mTORC1 signaling and the metabolic control of cell growth","volume":"45","author":"I Ben-Sahra","year":"2017","journal-title":"Curr Opin Cell Biol"},{"issue":"3","key":"pone.0248380.ref052","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.pcl.2015.03.005","article-title":"Tuberous sclerosis complex","volume":"62","author":"FJ DiMario","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"8","key":"pone.0248380.ref053","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082453","article-title":"Role of mTOR Signaling in Tumor Microenvironment: An Overview","volume":"19","author":"F Conciatori","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"15","key":"pone.0248380.ref054","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"K Inoki","year":"2003","journal-title":"Genes Dev"},{"issue":"10","key":"pone.0248380.ref055","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/aps.2015.68","article-title":"Toward rapamycin analog (rapalog)-based precision cancer therapy","volume":"36","author":"LH Meng","year":"2015","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"pone.0248380.ref056","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030755","article-title":"mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy","volume":"20","author":"T Tian","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0248380.ref057","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"H Hua","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"10","key":"pone.0248380.ref058","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-15-2631","article-title":"Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma","volume":"22","author":"DJ Kwiatkowski","year":"2016","journal-title":"Clin Cancer Res"},{"key":"pone.0248380.ref059","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-1-4939-7234-0_23","article-title":"Targeting the PI3K\/AKT\/mTOR Pathway in Bladder Cancer","volume":"1655","author":"A Sathe","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"15","key":"pone.0248380.ref060","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","article-title":"Response and acquired resistance to everolimus in anaplastic thyroid cancer","volume":"371","author":"N Wagle","year":"2014","journal-title":"N Engl J Med"},{"issue":"45","key":"pone.0248380.ref061","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"AY Choo","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"pone.0248380.ref062","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"M Laplante","year":"2012","journal-title":"Cell"},{"issue":"3","key":"pone.0248380.ref063","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4161\/cc.27355","article-title":"Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells","volume":"13","author":"A Alayev","year":"2014","journal-title":"Cell Cycle"},{"issue":"1","key":"pone.0248380.ref064","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1073\/pnas.1417015112","article-title":"Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells","volume":"112","author":"J Li","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"pone.0248380.ref065","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.15252\/embj.201796700","article-title":"Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients","volume":"36","author":"MR Woodford","year":"2017","journal-title":"EMBO J"},{"issue":"56","key":"pone.0248380.ref066","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.18632\/oncotarget.27217","article-title":"Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity","volume":"10","author":"MR Woodford","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"pone.0248380.ref067","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/hep.22685","article-title":"Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice","volume":"49","author":"SA Lang","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"pone.0248380.ref068","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s12276-019-0360-x","article-title":"Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1","volume":"52","author":"HK Park","year":"2020","journal-title":"Exp Mol Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T13:43:29Z","timestamp":1619185409000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248380"}},"subtitle":[],"editor":[{"given":"Diego","family":"Calvisi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":68,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248380","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.26.433022","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]}}}